C
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.
Investor insights
Funding rounds participated in
$461M sweet spot round size
Investor type
Public Company
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Funding rounds raised
Total raised
$461M
from investors over 1 rounds
C
Celldex Therapeutics raised $461M on March 29, 2024